<!DOCTYPE html>
<html lang="en">
    <head>
        <meta charset="UTF-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <meta http-equiv="X-UA-Compatible" content="ie=edge">
        <title>实体瘤15检测报告</title>
        <link rel="stylesheet" href='./comon.css'></link>
        <link rel="stylesheet" href='./15.css'></link>
        <script src="https://apps.bdimg.com/libs/jquery/2.1.4/jquery.min.js"></script>
    </head>
<body>
    <img  src="./img/dosImg.png"  style="width:100%" class="dosImg" />
    <div class="container">
        <div class="docTitle">
            <h3>肿瘤个体化诊疗基因检测</h3>
            <h4>Precision Oncology ＆ Personalized Treatment</h4>
            
        </div>
        <div class="common-role">
            <section class="display-bt">
                <div class="leftPart">
                    项目名称：
                </div>
                <div class="rightPart">
                    泛癌种基因检测
                </div>
            </section>
            <section class="display-bt">
                <div class="leftPart">
                    患者姓名：
                </div>
                <div class="rightPart">
                    吴显恩
                </div>
            </section>
            <section class="display-bt">
                <div class="leftPart">
                    样本编号：
                </div>
                <div class="rightPart">
                    36985593
                </div>
            </section>
            <section class="display-bt">
                <div class="leftPart">
                    送检医院：
                </div>
                <div class="rightPart">
                    
                </div>
            </section>
            <section class="display-bt">
                <div class="leftPart">
                    收样日期：
                </div>
                <div class="rightPart">
                    2020/7/04
                </div>
            </section>
            
            <section class="display-bt">
                <div class="leftPart">
                    报告日期：
                </div>
                <div class="rightPart">
                    2020/7/04
                </div>
            </section>
            
            
        
        </div>

        <div class="main-content main-content-15">
            <section class="main-part part0"  style="margin-top: 1000px;">
                <h1>
                    <span>目录</span>
                </h1>
                <ul>
                    <li>
                        <div class="display-bt"><a href="#mao1">患者信息</a>  <section>(3)</section> </div>
                        <ul class="inhertUl">
                            <li class="display-bt"><a href="#mao1-1">检测结果的临床意义解读及综合用药建议</a><section>(3)</section></li>
                        </ul>
                    </li>
                    <li>
                        <div class="display-bt"><a href="#mao2">样本和数据质控信息</a>  <section>(4)</section> </div>
                    </li>
                    <li>
                        <div class="display-bt"><a href="#mao3">CAPDX Lungpanel 15 简介</a>  <section>(4)</section> </div>
                    </li>
                    <li>
                        <div class="display-bt"><a href="#mao4">检测结果汇总</a>  <section>(5)</section> </div>
                        <ul class="inhertUl">
                            <li class="display-bt"><a href="#mao4-1">靶向药物相关基因变异</a><section>(5)</section></li>
                        </ul>
                    </li>
                    <li>
                        <div class="display-bt"><a href="#mao5">附录1</a>  <section>(8)</section> </div>
                        <ul class="inhertUl">
                            <li class="display-bt"><a href="#mao5-1">FDA、NMPA批准及NCCN指南建议可用于非小细胞肺癌治疗的靶向药物简介</a><section>(8)</section></li>
                        </ul>
                    </li>
                    <li>
                        <div class="display-bt"><a href="#mao6">附录2</a>  <section>(9)</section> </div>
                        <ul class="inhertUl">
                            <li class="display-bt"><a href="#mao6-1">本次检测所涉及的基因及其临床意义简介</a><section>(9)</section></li>
                        </ul>
                    </li>
                    <li>
                        <div class="display-bt"><a href="#mao7">附录3</a>  <section>(11)</section> </div>
                        <ul class="inhertUl">
                            <li class="display-bt"><a href="#mao7-1">可能使患者受益的临床试验研究</a><section>(11)</section></li>
                        </ul>
                    </li>
                    <li>
                        <div class="display-bt"><a href="#mao8">参考文献</a>  <section>(12)</section> </div>
                    </li>
                    <li>
                        <div class="display-bt"><a href="#mao9">产品声明</a>  <section>(14)</section> </div>
                    </li>
                </ul>
            </section>

            <section class="main-part part1" style="margin-top: 1000px;">
                <h1>
                    <span id="mao1">患者信息</span>
                </h1>
                <div class="tab1">
                    <ul>
                        <li>
                            <span style="width: 20%;">姓名</span>
                            <span style="width: 29%;">吴显恩</span>
                            <span style="width: 20%;">性别</span>
                            <span style="width: 29%;">男</span>
                        </li>
                        <li>
                            <span style="width: 20%;">年龄</span>
                            <span style="width: 29%;">18</span>
                            <span style="width: 20%;">样本编号</span>
                            <span style="width: 29%;">0075</span>
                        </li>
                        <li>
                            <span style="width: 20%;">样本类型</span>
                            <span style="width: 29%;">血液</span>
                            <span style="width: 20%;">病理诊断</span>
                            <span style="width: 29%;">肺腺癌</span>
                        </li>
                        <li>
                            <span style="width: 20%;">用药史</span>
                            <span style="width: 79%;">1</span>
                           
                        </li>
                        <li>
                            <span style="width: 20%;">家族史</span>
                            <span style="width: 79%;">1</span>
                           
                        </li>
                    </ul>
                    <p style="font-size: 12px;">注：以上信息（样本类型、病理诊断、用药史、家族史）均以患者送检时提供的信息为准，本次检测不对这些内容进行判读或解读。</p>
                </div>
                <h3 id="mao1-1">检测结果的临床意义解读及综合用药建议</h3>
                <div class="tab2">
                    <ul>
                        <li class="tabpart-title">
                            检测结果临床意义解读
                        </li>
                        <li>
                            <text style="width: 12.5%;">变异基因</text>
                            <text style="width: 12.5%;">变异解析</text>
                            <text style="width: 12.5%;">突变丰度</text>
                            <text style="width: 18%;" class="anotherText">
                                获批用于非小细胞肺癌治疗的
                                靶向药物
                            </text>
                            <text style="width: 21%;" class="anotherText">获批用于其他适应症且NCCN指南推荐用于非小细胞肺癌的靶向药物</text>
                            <text style="width: 18%;" class="anotherText">
                                可能获益的临床试验
                                研究药物
                            </text>
                        </li>
                        <li>
                            <text style="width: 12.5%;">---</text>
                            <text style="width: 12.5%;">---</text>
                            <text style="width: 12.5%;">---</text>
                            <text style="width: 18%;" >
                                ---
                            </text>
                            <text style="width: 21%;" >---</text>
                            <text style="width: 18%;" >
                                ---
                            </text>
                        </li>
                        <li class="tabpart-title">
                            综合用药建议
                        </li>
                        <li>
                            <span style="width: 25%;">可能获益的靶向药物</span> <text style="width: 74%;">无</text>
                        </li>
                        <li>
                            <span style="width: 25%;">可能获益的临床试验研究药物</span> <text style="width: 74%;">无</text>
                        </li>
                    </ul>
                    <p style="font-size: 12px;">注：  1. 本检测仅对送检样本负责，检测结果仅供医生参考。</p>
                    <p style="font-size: 12px;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.所测相关基因仅限于本实验室检测范围，超出本实验室检测范围的基因无法检出。</p>
                    <p style="font-size: 12px;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.所列药物和临床试验均未按照该患者潜在的预测疗效排序，也未按照其所属肿瘤类型疗效的相关证据可信度排序，本报告仅供参考。</p>
                    <p style="font-size: 12px;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.获批用于非小细胞肺癌治疗的靶向药物是指已被 FDA，NMPA 或欧盟批准上市的靶向药物。所有药物适应症以 FDA，NMPA 或欧盟批准的适应症为准。</p>
                </div>

            </section>
            <section class="main-part part2" style="margin-top: 1000px;">
                <h1>
                    <span id="mao2">样本和数据质控信息</span>
                </h1>
               <ul>
                   <li> <text style="width: 49%;">基因检测产品：</text><text  style="width: 50%;">CAPDX Lungpanel 15</text> </li>
                   <li> <text style="width: 49%;">检测技术：</text><text  style="width: 50%;">高通量靶向测序</text> </li>
                   <li> <text style="width: 49%;">DNA 提取总量：</text><text  style="width: 50%;">139.2 ng</text> </li>
                   <li> <text style="width: 49%;">平均测序深度：</text><text  style="width: 50%;">11391.86X</text> </li>
                   <li> <text style="width: 49%;">靶标区域 500X 以上覆盖度所占比例：</text><text  style="width: 50%;">99.8%</text> </li>
                   <li> <text style="width: 49%;">Uniformity：</text><text  style="width: 50%;">99.7%</text> </li>
               </ul>

            </section>
            <section class="main-part part3" style="margin-top: 1200px;">
                <h1>
                    <span id="mao3">CAPDX Lungpanel 15 简介</span>
                </h1>
                <p>CAPDX Lungpanel 15 基于二代测序技术，检测 15 个与非小细胞肺癌个性化治疗高度相关的基因，检测内容包括基因突变、重排和拷贝数变化。</p>
               <ul>
                   <li class="tabpart-title">靶向药物相关的14个基因</li>
                   <li> <text style="width: 25%;">ALK 融合/突变</text><text  style="width: 24%;">BRAF 突变</text> <text style="width: 25%;">BCL2L11(BIM) 缺失</text><text style="width: 24%;">EGFR 突变</text></li>
                   <li> <text style="width: 25%;">ERBB2(HER2) 插入</text><text  style="width: 24%;">KRAS 突变</text> <text  style="width: 25%;">MAP2K1(MEK1)突变</text><text  style="width: 24%;">MET 扩增/突变</text></li>
                   <li> <text style="width: 25%;">NTRK1 融合</text><text  style="width: 24%;">NTRK2 融合</text> <text  style="width: 25%;">NTRK3 融合</text><text  style="width: 24%;">PIK3CA 突变</text></li>
                  
                   <li> <text style="width: 25%;">RET 融合</text><text  style="width: 24%;">ROS1 融合</text> <text  style="width: 25%;">TP53突变</text><text  style="width: 24%;"> --- </text></li>
               </ul>

            </section>
            <section class="main-part part4" style="margin-top: 1200px;">
                <h1>
                    <span id="mao4">检测结果汇总</span>
                </h1>
                <h3 id="mao4-1" style="color:rgba(75,172,198,1);">靶向药物相关基因变异</h3>
               <ul>
                   <li class="tabpart-title display-bt" style="line-height:40px">
                       <div style="width: 13%;">基因</div>
                       <div style="width: 37%;">位点</div>
                       <div style="width: 37%;">检测结果</div>
                       <div style="width: 13%;">突变丰度</div>
                   </li>
                   <li class="display-bt"> 
                       <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">EGFR</div>
                       <ul style="width:87%" class="inhertUl">
                        
                            <li>
                                <text style="width: 42%">exon19 del</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                            <li>
                                <text style="width: 42%">exon21: L858R</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                            <li>
                                <text style="width: 42%">exon18: G719X</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                            <li>
                                <text style="width: 42%">exon20: S768I</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                            <li>
                                <text style="width: 42%">exon21: L861Q</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                            <li>
                                <text style="width: 42%">exon20: A763_Y764insFQEA</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                            <li>
                                <text style="width: 42%">exon20 ins</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                            <li>
                                <text style="width: 42%">exon20: T790M</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                            <li>
                                <text style="width: 42%">exon20: C797S</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                        
                       </ul>
                       
                    </li>
                    <li class="display-bt"> 
                        <div class="" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">BRAF</div>
                        <ul style="width:87%" class="inhertUl someUl">
                         
                             <li>
                                 <text style="width: 42%">V600E</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             <li>
                                 <text style="width: 42%">D594G</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             <li>
                                 <text style="width: 42%">G469A</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
 
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">KRAS</div>
                        <ul style="width:87%" class="inhertUl ">
                         
                             <li>
                                 <text style="width: 42%">G12X</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             <li>
                                 <text style="width: 42%">G13X</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                            
 
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class="bgColorB doubleHeight" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">MAP2K1<br>
                            (MEK1)</div>
                        <ul style="width:87%" class="inhertUl ">
                         
                             <li class="doubleLine" style="line-height:80px">
                                 <text style="width: 42%">K57N</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                            
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class=" doubleHeight" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">ERBB2
                            <br>
                            (HER2)</div>
                        <ul style="width:87%" class="inhertUl someUl">
                         
                             <li class="doubleLine" style="line-height:80px">
                                 <text style="width: 42%">exon20 ins</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                            
                        </ul>
                        
                     </li>
                  
                     <li class="display-bt"> 
                        <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">PIK3CA</div>
                        <ul style="width:87%" class="inhertUl ">
                         
                             <li>
                                 <text style="width: 42%">E542K</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             <li>
                                 <text style="width: 42%">E545K</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             <li>
                                 <text style="width: 42%">H1047R</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
 
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class=" doubleHeight" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">BCL2L11
                           
                            <br>
                            (BIM)</div>
                        <ul style="width:87%" class="inhertUl someUl">
                         
                             <li class="doubleLine" style="line-height:80px">
                                 <text style="width: 42%">intron2 del</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                            
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">ALK</div>
                        <ul style="width:87%" class="inhertUl ">
                         
                             <li>
                                 <text style="width: 42%">基因融合</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             <li>
                                 <text style="width: 42%">基因突变</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">NTRK1</div>
                        <ul style="width:87%" class="inhertUl ">
                         
                             <li>
                                 <text style="width: 42%">基因融合</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class="" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">NTRK2</div>
                        <ul style="width:87%" class="inhertUl someUl">
                         
                             <li>
                                 <text style="width: 42%">基因融合</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">NTRK3</div>
                        <ul style="width:87%" class="inhertUl ">
                         
                             <li>
                                 <text style="width: 42%">基因融合</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class="" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">RET</div>
                        <ul style="width:87%" class="inhertUl someUl">
                         
                             <li>
                                 <text style="width: 42%">基因融合</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">ROS1</div>
                        <ul style="width:87%" class="inhertUl ">
                         
                             <li>
                                 <text style="width: 42%">基因融合</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             
                        </ul>
                        
                     </li>
                     <li class="display-bt"> 
                        <div class="" style="width: 13%;height: auto;display:flex;align-items: center;justify-content:center;">MET</div>
                        <ul style="width:87%" class="inhertUl someUl">
                         
                             <li>
                                 <text style="width: 42%">MET基因扩增</text>
                                 <text style="width:42%">--</text>
                                 <text style="width:14%">--</text>
                             </li>
                             <li>
                                <text style="width: 42%">exon14 跳跃突变</text>
                                <text style="width:42%">--</text>
                                <text style="width:14%">--</text>
                            </li>
                             
                        </ul>
                        
                     </li>
                 
               </ul>
               <P style="font-size: 12px;">注：突变丰度是指在该位点所有等位基因中突变基因所占的百分比。</P>
            </section>
            <section class="main-part part5">
                <h1>
                    <span>重要声明</span>
                </h1>
                <div style='font-size:20px'>
                    <p>1.本报告结果只对本次送检样品负责，本实验室对以上检测结果保留最终解释权，如有疑义，请在收到结果后的3个工作日内与我们联系。</p>
                    <p>2.受检者的最终表型由肿瘤发展和其他外因共同作用产生，本报告仅供受检者参考，具体治疗请遵医嘱。</p>
                    <p>3.对受检者送检样品进行有限数量的位点检测不能揭示受检者可能存在的基因突变/基因多态性。基因突变/基因多态性/蛋白表达可能由于检测技术的局限性、样本采集或运输意外以及其他无法预知的因素等而未被发现。</p>
                    <p>4.本检测仅限于科学研究用途，不具备医嘱性质，具体治疗方案需由临床医生决定。部分基因与药物对应关系，目前仅限于科学研究或临床实验阶段，尚未进入临床指南，需临床医生酌情参考。</p>
                </div>
            </section>

            <section class="main-part part6" style="margin-top: 50px;">
                <h1>
                    <span>报告审核</span>
                </h1>
               <div class="display-bt">
                        <div>检测人：xxxx</div>

                        <div>复核人：z'z'z</div>
               </div>
               <div class="display-bt">
                    <div>日期：2020.12.23</div>

                    <div>日期：202012.32</div>
                </div>
            </section>
            <section class="main-part part7" style="margin-top: 1400px;">
                <h1>
                    <span id="mao5">附录1</span> <text id="mao5-1" style="color: #4bacc6;">FDA、NMPA批准及NCCN指南建议可用于非小细胞肺癌治疗的靶向药物简介</text>
                </h1>
                <ul>
                    <li class="tabpart-title display-bt" style="line-height:60px;text-align:left;">
                        <div style="width: 20%;border-right: 1px solid rgb(145,205,220);padding-left:10px">基因</div>
                        <div style="width: 80%;padding-left:10px">靶向药物</div>
                        
                    </li>
                    <li class="display-bt bgColorB">
                        <div style="width: 20%;border-right: 1px solid rgb(145,205,220);padding-left:10px;height: auto;display:flex;align-items: center;">EGFR</div>
                        <div style="width: 80%;padding:10px;">
                            FDA批准EGFR抑制剂吉非替尼（gefitinib）、厄洛替尼（erlotinib）、阿法替尼（afatinib）、达可替尼（dacomitinib）
                            用于治疗EGFR突变的非小细胞肺癌，批准奥希替尼（osimertinib，AZD9291）用于治疗 EGFR T790M 突变的非小细胞肺癌。NMPA批准EGFR抑制剂埃克替尼（icotinib）用于治疗EGFR突变的非小细胞肺癌
                        </div>
                    </li>
                    <li class="display-bt ">
                        <div style="width: 20%;border-right: 1px solid rgb(145,205,220);padding-left:10px;height: auto;display:flex;align-items: center;">ALK</div>
                        <div style="width: 80%;padding:10px;">
                            FDA批准ALK抑制剂克唑替尼（crizotinib）、塞瑞替尼（ceritinib）、阿来替尼（alectinib）、布加替尼（brigatinib）用于治疗ALK融合阳性的非小细胞肺癌。
                        </div>
                    </li>
                    <li class="display-bt bgColorB">
                        <div style="width: 20%;border-right: 1px solid rgb(145,205,220);padding-left:10px;height: auto;display:flex;align-items: center;">ROS1</div>
                        <div style="width: 80%;padding:10px;">
                            FDA批准克唑替尼（crizotinib）用于ROS1阳性非小细胞肺癌。NCCN指南建议，塞瑞替尼（ceritinib）用于ROS1阳性非小细胞肺癌。
                        </div>
                    </li>
                    <li class="display-bt ">
                        <div style="width: 20%;border-right: 1px solid rgb(145,205,220);padding-left:10px;height: auto;display:flex;align-items: center;">RET</div>
                        <div style="width: 80%;padding:10px;">
                            NCCN指南建议，卡博替尼（cabozantinib）、凡德他尼（vandetanib）用于RET融合的非小细胞肺癌。
                        </div>
                    </li>
                    <li class="display-bt bgColorB">
                        <div style="width: 20%;border-right: 1px solid rgb(145,205,220);padding-left:10px;height: auto;display:flex;align-items: center;">MET</div>
                        <div style="width: 80%;padding:10px;">
                            NCCN指南建议，克唑替尼（crizotinib）用于MET扩增和第14号外显子跳跃的非小细胞肺癌。
                        </div>
                    </li>
                    <li class="display-bt ">
                        <div style="width: 20%;border-right: 1px solid rgb(145,205,220);padding-left:10px;height: auto;display:flex;align-items: center;">BRAF</div>
                        <div style="width: 80%;padding:10px;">
                            FDA批准达拉菲尼（dabrafenib）和曲美替尼（trametinib）联合用于 BRAF V600E 突变阳性的转移性非小细胞肺癌；NCCN指南指出如果联合用药不耐受，可选择达拉菲尼（dabrafenib）或维莫非尼（vemurafenib）单剂治疗。
                        </div>
                    </li>
                    <li class="display-bt bgColorB">
                        <div style="width: 20%;border-right: 1px solid rgb(145,205,220);padding-left:10px;height: auto;display:flex;align-items: center;">ERBB2(HER2)</div>
                        <div style="width: 80%;padding:10px;">
                            FDA批准曲妥珠单抗-美坦新偶联物（Ado-trastuzumab emtansine）用于HER2阳性转移性乳腺癌。NCCN指南建议，Ado-trastuzumab emtansine用于HER2突变的非小细胞肺癌。
                        </div>
                    </li>
                    <li class="display-bt ">
                        <div style="width: 20%;border-right: 1px solid rgb(145,205,220);padding-left:10px;height: auto;display:flex;align-items: center;">NTRK</div>
                        <div style="width: 80%;padding:10px;">
                            FDA批准TRK抑制剂拉罗替尼（larotrectinib）用于治疗TRK融合癌患者。
                        </div>
                    </li>
                </ul>
               
            </section>
            <section class="main-part part8" style="margin-top: 1000px;">
                <h1>
                    <span id="mao6">附录2</span> <text id="mao6-1" style="color: #4bacc6;">本次检测所涉及的基因及其临床意义简介</text>
                </h1>
              <ul>
                <li class="tabpart-title display-bt" style="line-height:60px;text-align:left;">
                    <div style="width: 13%;border-right: 1px solid rgb(145,205,220);padding-left:10px">基因</div>
                    <div style="width: 24%;border-right: 1px solid rgb(145,205,220);padding-left:10px">位点</div>
                    <div style="width: 33%;border-right: 1px solid rgb(145,205,220);padding-left:10px">临床意义</div>
                    <div style="width: 30%;border-right: 1px solid rgb(145,205,220);padding-left:10px">靶向药物</div>
                    
                </li>
                <li class="display-bt">
                    <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">EGFR</div>
                    <ul style="width:87%" class="inhertUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                <div>exon19 del</div>
                                <div>L858R</div>
                                <div>G719X</div>
                                <div>S768I</div>
                                <div>L861Q</div>
                                <div>A763_Y764insFQEA</div>
                            </div>
                            <div class="li-div" style="width:38%">EGFR TKI敏感位点，其中exon19 del，L858R较常见，A763_Y764insFQEA和其它3种突变较少见。</div>
                            <div class="li-div" style="width:34.5%">
                                <div>吉非替尼（gefitinib）</div>
                                <div>厄洛替尼（erlotinib）</div>
                                <div>埃克替尼（icotinib）</div>
                                <div>阿法替尼（afatinib）</div>
                                <div>奥希替尼（osimertinib）</div>
                                <div>达可替尼（dacomitinib）</div>
                            </div>
                        </li>
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                exon20 ins
                            </div>
                            <div class="li-div" style="width:38%">EGFR TKI耐药位点，与EGFR TKI敏感位点共存时EGFR-TKI效果不佳。</div>
                            <div class="li-div" style="width:34.5%">
                                --
                            </div>
                        </li>
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                T790M
                            </div>
                            <div class="li-div" style="width:38%">第一代EGFR TKI耐药位点，与EGFR TKI敏感位点共存时一代或二代EGFR靶向药物效果不佳；为第三代EGFR TKI敏感位点，携带有该突变时对第三代EGFR TKI敏感。</div>
                            <div class="li-div" style="width:34.5%">
                                奥希替尼（osimertinib）
                            </div>
                        </li>
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                C797S
                            </div>
                            <div class="li-div" style="width:38%">第三代EGFR TKI耐药位点。</div>
                            <div class="li-div" style="width:34.5%">
                                --
                            </div>
                        </li>
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">ALK</div>
                    <ul style="width:87%" class="inhertUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                基因融合
                            </div>
                            <div class="li-div" style="width:38%">ALK基因融合（与EML4，KIF5B，TFG，KLC1，PTPN3基因发生融合）对ALK抑制剂敏感。</div>
                            <div class="li-div" style="width:34.5%">
                                <div>克唑替尼（crizotinib）</div>
                                <div>塞瑞替尼（ceritinib）</div>
                                <div>阿来替尼（alectinib）</div>
                                <div>布加替尼（brigatinib）</div>
                              
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">ROS1</div>
                    <ul style="width:87%" class="inhertUl someUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                基因融合
                            </div>
                            <div class="li-div" style="width:38%">ROS1基因融合（与SLC34A2, CD74, TPM3, SDC4, EZR, LRIG3, KDELR2, CCDC6基因发生融合）对ROS1抑制剂敏感。</div>
                            <div class="li-div" style="width:34.5%">
                                <div>克唑替尼（crizotinib）</div>
                                <div>塞瑞替尼（ceritinib）</div>
                                
                              
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">RET</div>
                    <ul style="width:87%" class="inhertUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                基因融合
                            </div>
                            <div class="li-div" style="width:38%">RET基因融合（与KIF5B, CCD6, NCOA4, TRIM33基因发生融合）对RET抑制剂敏感；针对该靶点的药物目前处于临床试验阶段。</div>
                            <div class="li-div" style="width:34.5%">
                               
                                <div> 卡博替尼（cabozantinib）（临床试验阶段）</div>
                                <div>凡德他尼（vandetanib）（临床试验阶段）</div>
                                
                              
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">PIK3CA</div>
                    <ul style="width:87%" class="inhertUl someUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                               <div>E542K</div>
                               <div>E545K</div>
                               <div>H1047R</div>
                            </div>
                            <div class="li-div" style="width:38%">PIK3CA基因突变的患者可能对PIK3抑制剂敏感；PIK3CA基因突变可能是EGFR TKI治疗的获得性耐药机制，针对该靶点的药物目前处于临床试验阶段。</div>
                            <div class="li-div" style="width:34.5%">
                                <div>Taselisib（临床试验阶段）</div>
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">KRAS</div>
                    <ul style="width:87%" class="inhertUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                <div>G12X</div>
                                <div>G13X</div>
                                
                            </div>
                            <div class="li-div" style="width:38%">该靶点目前尚无靶向药物上市，但对其下游靶点MEK1的靶向药物可能敏感；该靶点同时是EGFR靶向药物的耐药位点，携带有KRAS基因突变的患者EGFR TKI效果不好。</div>
                            <div class="li-div" style="width:34.5%">
                               
                                ---
                                
                              
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">BRAF</div>
                    <ul style="width:87%" class="inhertUl someUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%;height: inherit;" class="li-div">
                              V600E
                              
                            </div>
                            <div class="li-div" style="width:38%;height: inherit;">BRAF基因突变（V600E）对BRAF抑制剂敏感。</div>
                            <div class="li-div" style="width:34.5%">
                                <div>达拉菲尼（dabrafenib）+曲美</div>
                                <div>替尼（trametinib）</div>
                                <div>维莫非尼（vemurafenib）</div>
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">ERBB2<br>
                        (HER2)</div>
                    <ul style="width:87%" class="inhertUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                <div>exon20 ins</div>
                                
                                
                            </div>
                            <div class="li-div" style="width:38%">HER2插入（20号外显子插入）对Ado-trastuzumabemtansine可能敏感。</div>
                            <div class="li-div" style="width:34.5%">
                               
                                Ado-trastuzumabemtansine
                                
                              
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">BCL2L11<br>
                        (BIM)</div>
                    <ul style="width:87%" class="inhertUl someUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%;height: inherit;" class="li-div">
                                intron2 del
                              
                            </div>
                            <div class="li-div" style="width:38%;height: inherit;">BIM缺失（2号内含子）可能对EGFR TKI耐药或削弱TKI疗效。</div>
                            <div class="li-div" style="width:34.5%">
                                --
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">MAP2K1<br>
                        (MEK1)</div>
                    <ul style="width:87%" class="inhertUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%" class="li-div">
                                <div>K57N</div>
                                
                                
                            </div>
                            <div class="li-div" style="width:38%">MEK1突变（K57N）可能对EGFR TKI耐药；针对该靶点的药物目前处于临床试验阶段。</div>
                            <div class="li-div" style="width:34.5%">
                               
                                --
                                
                              
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">MET</div>
                    <ul style="width:87%" class="inhertUl someUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%;height: inherit;" class="li-div">
                               <div>基因扩增</div>
                               <div>exon14跳跃突变</div>
                              
                            </div>
                            <div class="li-div" style="width:38%;height: inherit;">MET基因扩增对MET抑制剂敏感；<br>MET扩增也是EGFR TKI耐药的重要机制之一。</div>
                            <div class="li-div" style="width:34.5%">
                               <div>克唑替尼（crizotinib）（临床试验阶段）</div>
                            </div>
                        </li>
                       
                    </ul>
                </li>
                <li class="display-bt">
                    <div class="bgColorB" style="width: 13%;height: auto;display:flex;align-items: center;padding-left: 10px;">NTRK1/2/3</div>
                    <ul style="width:87%" class="inhertUl">
                        <li style="height: auto;display:flex;align-items: center;justify-content:center;">
                            <div style="width:27.5%;height: inherit;" class="li-div">
                               <div>基因融合</div>
                               
                              
                            </div>
                            <div class="li-div" style="width:38%;height: inherit;">NTRK基因融合对拉罗替尼（larotrectinib），一种口服TKI，敏感</div>
                            <div class="li-div" style="width:34.5%">
                               <div>拉罗替尼（larotrectinib）（临床试验阶段）</div>
                            </div>
                        </li>
                       
                    </ul>
                </li>
              </ul>
               
            </section>
            <section class="main-part part9">
                <h1>
                    <span id="mao7">附录3</span> <text id="mao7-1" style="color: #4bacc6;">可能使患者受益的临床试验研究  </text>
                </h1>
               <p>NCCN（美国国家综合癌症网络组织）认为对于任何癌症患者的最好管理就是参加临床试验。应该特别鼓励患者参与临床试验。</p>
               <p>以下为国际、国内临床试验研究网址，可结合网站提供的临床试验研究信息及患者的临床信息查询、参与其中的临床试验研究项目。</p>
               <h3>1. 美国临床试验数据库 https://clinicaltrials.gov</h3>
               <p>ClinicalTrials.gov 是美国国立医学图书馆(NML)与美国食品与药物管理局(FDA)开发并运行的临床试验研究数据库。主要向医疗卫生人员、患者和社会大众提供临床试验的查询服务；同时向机构和医学科研人员提供临床试验的注册服务，是全球最重要的临床试验注册机构之一，其注册和查询临床试验均为免费，被誉为公开化、国际化临床试验注册的典范。</p>
                <h3>2. 药物临床试验登记与信息公示平台 http://www.chinadrugtrials.org.cn</h3>
                <p>药物临床试验登记与信息公示平台是国家食品药品监督管理总局参照世界卫生组织要求和国际惯例建立的临床试验信息平台，实施药物临床试验登记与信息公示。凡获国家药品监督管理部门临床试验批件并在我国进行的临床试验（含生物等效性试验、PK 试验、I、Ⅱ、Ⅲ、Ⅳ期试验等），均应登陆信息平台按要求进行临床试验登记与信息公示。</p>
                <h3>3. 中国临床试验注册中心 www.chictr.org.cn</h3>
                <p>中国临床试验注册中心（Chinese Clinical Trial Registry, ChiCTR）是由卫生部指定代表我国参加世界卫生组织国际临床试验注册平台的国家临床试验注册中心；是世界卫生组织国际临床试验注册平台的一级注册机构，是一个非赢利的学术机构。中国临床试验注册中心的注册程序和内容完全符合WHO 国际临床试验注册平台（WHO ICTRP）和国际医学期刊编辑委员会（ICMJE）的标准。中国临床试验注册中心接受在中国和全世界实施的临床试验注册，将临床试验的设计方案及一些必要的研究信息向公众透明；将注册试验信息提交世界卫生组织国际临床试验注册平台供全球共享。</p>
            
            </section>
            <section class="main-part part10" style="margin-top: 1000px;">
                <h1>
                    <span id="mao8">参考文献</span> <text style="color: #4bacc6;"> </text>
                </h1>
               <p>[1].NCCN Clinical Practice Guidelines in Oncology：Non-Small Cell Lung Cancer（Version 3.2019-January 18, 2019）</p>
               <p>[2].Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum pemetrexed in EGFR T790M positive lung cancer. N Engl J Med 2017;376:629-640.</p>
               <p>[3].JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113-125.</p>
               <p>[4].Yuankai Shi, Yan Sun, Cuimin Ding, et al. China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version). Zhongguo Fei Ai Za Zhi. 2015 Jul 20; 18(7): 397–400.</p>
                <p>[5].Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol 2017;35:2613-2618.</p>
                <p>[6].Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-1971.</p>
                <p>[7].Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013; 3:630-635.</p>
                <p>[8].Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol 2016;17:1653-1660</p>
                <p>[9].Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol 2017;28:292-297</p>
                <p>[10].Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-946.</p>
                <p>[11].Camidge RD, Ou S-HI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer. J Clin Oncol 2014;32(Suppl 5): Abstract 8001.</p>
                <p>[12].Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Cancer Discov 2015;5:850-859.</p>
                <p>[13].Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5:842-849.</p>
                <p>[14].Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and cMET overexpresion. J Clin Oncol 2016;34:721-730.</p>
                <p>[15].Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)- mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017;18:1307-1316.</p>
                <p>[16].Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E) mutant metastatic non small cell lung cancer: an open label, multicentre phase 2 trial. Lancet Oncol 2016;17:984-993.12</p>
                <p>[17].Planchard D, Besse B, Kim TM, et al. Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study [abstract]. J Clin Oncol 2017;35: Abstract 9075.</p>
                <p>[18].Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial. J Clin Oncol 2018;36:2532-2537.</p>
                <p>[19].Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-7241.</p>
                <p>[20].Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013;5:216ra177.</p>
                <p>[21].Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013;12:220-229.</p>
                <p>[22].Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 2013;8:179-184.</p>
                <p>[23].Lund-Iversen M, Kleinberg L, Fjellbirkeland L, et al. Clinicopathological characteristics of 11 NSCLC patients with EGFRexon 20 mutations. J Thorac Oncol 2012;7:1471-1473.</p>
                <p>[24].Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012;13:e23-31.</p>
                <p>[25].Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun; 21(6): 560–562.</p>
                <p>[26].Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23;3(75):75ra26.</p>
                <p>[27].Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.</p>
                <p>[28].Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26:1472-1478.</p>
                <p>[29].Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013;31:1112-1121.</p>
                <p>[30].Gautschi O, Milia J, Cabarrou B, et al. Targeted therapy for patients with BRAF-mutant lung cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015;10:1451-1457.</p>
                <p>[31].Ng KP, Hillmer AM, Chuah CT,et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Nat Med. 2012 Mar 18;18(4):521-8.</p>
                <p>[32].Amit M. Oza, Johanne Ingrid Weberpals, Diane M, et al. An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.J Clin Oncol 33, 2015 (suppl; abstr 5506)</p>
                <p>[33].Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18;316(5827):1039-43.</p>
            
            </section>
            <section id="tests" class="main-part part11">
                <h1>
                    <span id="mao9">产品声明</span> <text style="color: #4bacc6;"> </text>
                </h1>
                <ul>
                    <li class="tabpart-title" style='text-align: left;padding-left:20px;line-height:60px'>
                        关于产品
                    </li>
                    <li class='display-bt items'>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:30%'>给出标志物的医学意义</div>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:70%'>本报告主要检测非小细胞肺癌治疗、预后等相关基因的变异情况。报告给出的这些变异信息和无变异信息可为临床医生对受检者的治疗提供参考，受检者请在临床医生的指导下阅读本报告</div>
                    </li>
                    <li class='display-bt items'>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:30%'>说明</div>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:70%'>一个生物标志物变异的发现并不意味着必定会对某一种药物或疗法有效，同样没有检测到生物标志物也不代表一定会对任何药物或疗法都无效。</div>

                    </li>
                    <li class='display-bt items'>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:30%'>基因变异和药物排名不分先后顺序</div>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:70%'>一个生物标志物变异的发现并不意味着必定会对某一种药物或疗法有效，同样没有检测到生物标志物也不代表一定会对任何药物或疗法都无效。</div>
                        
                    </li>
                    <li class='display-bt items'>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:30%'>不提供证据等级</div>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:70%'>本报告不对潜在的临床受益药物或无效药物的证据来源或等级作出评估。</div>
                        
                    </li>
                    <li class='display-bt items'>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:30%'>不保证临床受益</div>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:70%'>本报告不对任何患者承诺或保证某一药物在治疗中有效，也不承诺某一药物在治疗中治疗无效。</div>
                        
                    </li>
                    <li class='display-bt items'>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:30%'>不保证赔偿</div>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:70%'>本公司不承诺或保证，无论公立或私营的医疗服务机构、保险公司或其他第三方付款人会向患者偿还该产品检测费用。</div>
                        
                    </li>
                    <li class='display-bt items'>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:30%'>治疗方案由医生决策</div>
                        <div style='height:auto;display:flex;align-items:center;padding-left: 20px;width:70%'>本报告提及到的药物可能对某一特定患者并不适用。任何一个或所有潜在有效药物的选取或无效药物的弃选都由医生慎重决定。临床医生在给出推荐治疗方案时，需要综合考虑本检测报告信息和患者的其他相关信息。</div>
                        
                    </li>
                    <li class="items" style='padding:20px'>
                        患者的治疗方案决策必须基于医生的医学判断，还需要考虑到患者的所有可用信息，包括患者病史和家族史、体检、其他的医学检测信息及患者喜好，并遵照医院给出的护理标准，医生的决策不能仅依赖于某一单个检测，如此次检测和报告中给出的信息，本报告基于科研进展得出某些药物更加敏感的结论，将这些药物标注为可关注，但临床实践结果尚需研究，本报告不是临床诊断报告，不具备医嘱性质，供医生参考，治疗方案由医生决策。
                    </li>
                    <li class="items" style='padding:20px'>有些样本或变异特征会降低检测敏感度，如异质性样本中的亚克隆变异、低样本质量、大片段的缺失或插入、重复或高同源序列等。使用肿瘤组织来源的DNA检测时，碰到此类问题不在报告中体现</li>
                </ul>
            </section>

        </div>
    </div>
</body>
<script>
    $(document).ready(function () {
       
        
    })


</script>
</html>